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Summary 43 
Context. Measurement of IGF-I is essential for diagnosis and management of patients with 44 
disorders affecting the somatotropic axis. However, even when IGF-I kit manufacturers 45 
follow recent consensus guidelines, different kits can give very different results for a given 46 
sample.  47 
Objectives. We sought to establish normative data for six IGF-I assay kits, based on a large 48 
random sample of the French general adult population. 49 
Subjects and Methods: In a cross-sectional multicenter cohort study (ClinicalTrials.gov 50 
Identifier: NCT01831648), we measured IGF-I in 911 healthy adults (18-90 years) with six 51 
immunoassays (iSYS, LIAISON XL, IMMULITE, IGFI RIACT, Mediagnost ELISA, and 52 
Mediagnost RIA). Pairwise concordance between assays was assessed with Bland-Altman 53 
plots for both IGF-1 raw data and standard deviation scores (SDS), as well as with the 54 
percentage of observed agreement and the weighted Kappa coefficient for categorized IGF-I 55 
SDS. 56 
Results: Normative data included the range of values (2.5 to 97.5 percentiles) given by the six 57 
IGF-I assays according to age group and sex. A formula for SDS calculation is provided. 58 
While the lower limits of the reference intervals of the six assays were similar, the upper 59 
limits varied markedly. Pairwise concordances were moderate to good (0.38 to 0.70). 60 
Conclusion. Despite being obtained in the same healthy population, the reference intervals of 61 
the six commercial IGF-1 assay kits showed noteworthy differences. Agreement between 62 
methods was moderate to good. 63 
 64 
  65 
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Growth hormone (GH) exerts its effects on target tissues either directly or via the production 66 
of insulin-like growth factor 1 (IGF-I). Accurate measurement of IGF-I in serum is crucial for 67 
diagnosis and management of disorders affecting the somatotropic axis, particularly GH 68 
excess (acromegaly) and GH deficiency (GHD). However, even if manufacturers follow the 69 
recommendations of the Consensus Group on the Standardization and Evaluation of GH and 70 
IGF-I Assays (1), the different commercial IGF-I assay kits can give very different results for 71 
the same sample, with up to a 2.5-fold difference between the lowest and highest values (2). 72 
This inter-method variability is generally explained by calibration against different IGF-I 73 
reference preparations (3), and differences in the efficiency of methods used to remove IGF-74 
binding proteins (IGFBPs) (4). In theory, this should not be a problem in clinical practice, as 75 
kits that give higher values should have higher normal limits, and patients should thus be 76 
consistently classified.  77 
However, it is very difficult to establish reference values for IGF-I. Indeed, serum IGF-I 78 
concentrations increase with children's age and pubertal stage, while they fall with age in 79 
adults (5). Furthermore, the distribution of IGF-I values in an apparently healthy population is 80 
non Gaussian, and this necessitates complex mathematical transformation to obtain reference 81 
intervals for each age group. For this reason, it is essential to generate reference values after 82 
stratifying a large healthy population into age groups. Another problem is that IGF-I 83 
concentrations are influenced by many factors other than GH concentrations, including 84 
nutritional status and BMI, use of hormone replacement therapy by post-menopausal women, 85 
depending on the administration route (6-8), kidney and liver function, and diabetic status (9). 86 
Reference IGF-I values may therefore be influenced by the inclusion criteria used to select the 87 
reference population sample. This could have important implications for diagnosis and 88 
therapeutic decision-making, as a given patient could be classified as having a normal IGF-I 89 
concentration with one method but an abnormal value with another method. Several studies 90 
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suggest that the main reason for inter-laboratory variability in patient classification is the use 91 
of different populations to establish reference values for the different IGF-I assays (2,10,11). 92 
It is currently difficult to monitor an individual patient with different IGF-I assays, even if the 93 
results are all expressed in the same units (ng/ml). It is thus recommended to establish 94 
specific reference ranges for each assay, and to apply common, well-defined inclusion criteria 95 
to the reference population (1). It is also recommended, for the comparison of values obtained 96 
with different assays in the same patient, to express each IGF-I result as an SD score (SDS) 97 
with reference to the normative data for the assay in question, after appropriate transformation 98 
for data non normality. We reasoned that the best way to overcome this variability would be 99 
to apply all the commercial kits used in clinical laboratories to a battery of samples from the 100 
same well-defined reference population, and to use the same mathematical transformation to 101 
calculate reference ranges from the raw data. 102 
The aim of this study was thus to establish normative data for six commercial IGF-1 assays in 103 
a large random sample of healthy subjects from the French general population representing all 104 
adult age groups (about 100 subjects per decade), as recommended by the Consensus Group 105 
on the Standardization and Evaluation of GH and IGF-I assays (1). Serum samples from the 106 
reference population were tested with six commercial assay kits available in France at the 107 
time of this study, after careful exclusion of subjects with medical conditions or medications 108 
that might affect their IGF-I concentration. The data were analyzed to obtain the range (2.5 to 109 
97.5 percentiles) in mass units. The standard deviation scores were used to compare the six 110 
assays. 111 
  112 
Subjects and Methods 113 
IGF-I assay characteristics 114 
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Six immunoassays (iSYS, LIAISON XL, IMMULITE, IGFI RIACT, Mediagnost ELISA, and 115 
Mediagnost RIA) were used to measure the IGF-I concentration in each healthy subject. The 116 
main characteristics of the assays, and the mathematical models used to determine normative 117 
data, where relevant (12-14), are shown in Table 1. 118 
 119 
Healthy subjects 120 
The subjects were part of a large cohort of French healthy adults (VARIETE). The VARIETE 121 
cohort was an open, prospective, national, multicenter, non randomized study of healthy 122 
volunteers, designed to establish normative data for IGF-I and other hormones in the French 123 
general adult population representing all age groups (about 100 subjects per decade from 18 124 
to 90 years) (ClinicalTrials.gov Identifier: NCT01831648). A total of 972 healthy subjects 125 
with BMI values between 19 and 28 kg/m² were recruited in 10 centers throughout France 126 
between 2010 and 2011. Our objective of including 1000 subjects was not achieved due to 127 
difficulties for obtaining an accurate number of subjects in the older age categories (>70 128 
years) fulfilling all the inclusion criteria and without exclusion criteria before the end of our 129 
inclusion period. Subjects with medical conditions or medications that might affect IGF-I 130 
serum levels were excluded (see Supplemental Appendix). Each subject had a clinical 131 
examination, personal medical history-taking and general examination, including careful 132 
evaluation of nutritional and gonadal status. Standard laboratory tests (plasma sodium, 133 
potassium, calcium, phosphate and creatinine, glycemia, total cholesterol, liver enzymes, 134 
TSH, blood cell count, albuminemia, prothrombin time, as well as HIV and HCV serologies) 135 
were then performed, and 80 mL of blood (50 mL without anticoagulant and 30 mL in 136 
EDTA-containing tubes) was sampled and promptly centrifuged (2000 g, 4°C). Serum and 137 
plasma were aliquoted, frozen, and stored at -80°C until hormone measurements.  138 
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All healthy subjects gave their written informed consent to participate in the study, which was 139 
approved by the Paris-Sud Ethics committee before the beginning of the study.  140 
 141 
Statistical methods 142 
The distribution of IGF-1 values obtained with each assay was skewed, and was thus first 143 
normalized by means of sex- and age-specific Box-Cox power transformation. Student’s t test 144 
and Levene’s test were then used to assess equality of means and homogeneity of variances 145 
between men and women in each age group. As men and women had significantly different 146 
IGF-1 levels, centile curves were constructed separately for each sex. 147 
Age- and sex-specific centile curves were constructed for each assay by using the LMS 148 
method (12) implemented in the GAMLSS software package version 4.3-1 (15) of R software 149 
version 3.1.2 (2014-10-31) (R Core Team (2014). R: A language and environment for 150 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria.URL 151 
http://www.R-project.org/.). The LMS method enables smooth curves to be estimated for 152 
percentiles after normalization (by Box-Cox power transformation) and standardization of the 153 
data. The parameters L (for skewness), M (for median) and S (for the coefficient of variation) 154 
were also computed for each age and sex class. SD scores (SDS) were calculated as z = 155 
[(IGF-1 / M)L- 1]/(L × S), where IGF-I is the raw value given by the assay (in ng/mL). For 156 
each technique, SDS were categorized as low, normal or high according to their positions 157 
relative to both the 2.5th and 97.5th percentiles. 158 
Once the L, M and S parameters for each category of age and sex had been obtained, the 159 
lower and upper reference interval limits were determined for each assay by fixing z at -1.96 160 
and 1.96, respectively, and then mathematically back-transforming the SD score formula. 161 
Pairwise concordance between assays was assessed with scatter plots and Bland-Altman plots 162 
for both IGF-1 raw values and SDS values, as well as with the percentage of observed 163 
  -/22- 8 
agreement (total number of agreements divided by the total number of patients tested with 164 
both assays) and the linearly weighted Kappa coefficient for categorized IGF-1 SDS (16,17). 165 
An overall kappa coefficient (16) and Friedman’s test were computed for global comparison 166 
of all assays at the same time. Landis and Koch’s table was followed for interpretation of 167 
Kappa values (18).  168 
Unless otherwise stated, SAS software was used for all statistical analyses (Statistical 169 
Analysis System, version 9.4, SAS Institute, Cary, N.C., USA). 170 
 171 
Results 172 
 173 
1- Description of the population 174 
Nine hundred seventy-two subjects were initially recruited, of whom 52 were excluded 175 
because of abnormal values in the standard laboratory screening tests. A further 9 subjects 176 
were excluded because of missing information on pregnancy status or viral serology. The 177 
study population thus consisted of 911 subjects (470 males), comprising respectively 101, 178 
118, 99, 98, 103, 102, 108, 97 and 85 subjects in the 18-20, 21-23, 24-26, 27-29, 30-39, 40-179 
49, 50-59, 60-69, 70-89 year age groups. Mean BMI was 23.0 ± 2.4 kg/m2. 180 
 181 
2- IGF-I reference intervals obtained with the six assays 182 
The IGF-I reference intervals (2.5th-97.5th percentiles) obtained with the six immunoassays 183 
are shown in Table 2 according to age and sex. Supplemental Figure 1 shows individual 184 
points and fitted percentiles (2.5%, 50% and 97.5%) for males and females in each IGF-I 185 
assay. 186 
A calculator available online (http://ticemed_sa.upmc.fr/sd_score/) or by using Apps (IGF-I 187 
SD_score) downloadable for Android from Google Play and for iOS from Apple Store (free 188 
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of charge) allows to obtain individual IGF-I SDS after entering the name of the assay, the 189 
individual IGF-I value obtained with the assay, and the sex and age of the individual. 190 
The six reference intervals for males and females are plotted on the same graph in Figure 1. 191 
While the lower limits of the reference intervals (2.5th percentiles) were similar, the upper 192 
limits (97.5th percentiles) varied markedly from one assay to another.  193 
3- Comparison of IGF-I levels given by the six assays 194 
The results obtained with each IGF-I assay were compared with those obtained with each of 195 
the other five assays. Scatter plots and Bland-Altman plots based on raw values and SDS for 196 
each pair of assays are shown in Supplemental Figure 2 197 
Whatever the assay, IGF-I concentrations were generally higher in women than in men until 198 
the age of 59 years (this was significant for the age ranges 18-20 and 24-26 years). From the 199 
age of 60 years, IGF-I levels were slightly higher in men than in women, although the gender 200 
difference was smaller than in the younger age groups and was only significant for Immulite, 201 
Mediagnost Elisa and Mediagnost RIA. 202 
Two examples of inter-assay comparisons are shown in Figure 2. The results obtained with 203 
iSYS and Mediagnost RIA were in good overall agreement, with no significant bias as 204 
assessed by Bland-Altman plots (Figure 2 A, B, C and D). In contrast, the results obtained 205 
with LIAISON XL and Mediagnost RIA were not in good agreement (Figure 2 E, F, G and 206 
H). 207 
Pairwise assay concordances assessed with the weighted Kappa coefficient for categorized 208 
IGF-1 SDS are shown in Table 3. The concordances were moderate to good (0.38 to 0.70), 209 
although the percentages of observed agreement were quite high (94% to 97%). 210 
Overall agreement was moderate as overall Kappa coefficient was 0.55. Both in men and 211 
women, global inter-assay comparison showed significant differences (p<0.0001) on raw 212 
values but not on SDS values (p=0.26 and p=0.36, respectively). 213 
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Table 4 shows pairwise concordances between the reference intervals provided by the 214 
manufacturer and those obtained in the VARIETE cohort, as assessed by the Kappa 215 
coefficient and the percentage agreement for each IGF-I assay. The concordances and 216 
percentages of observed agreement were generally poor. 217 
 218 
Discussion 219 
We report reference intervals for IGF-I concentrations obtained with six 220 
immunoassays in the same population of nearly 900 French healthy subjects aged from 18 to 221 
90 years, in keeping with the 2011 recommendations of the Consensus Group on the 222 
Standardization and Evaluation of GH and IGF-I assays (1). The population comprised about 223 
100 subjects per age decade, and specific reference intervals were calculated for each sex and 224 
age group. The reference intervals varied from one assay to another: the lower limits of the 225 
normal range (2.5th percentile) were quite similar with the six methods, but the upper limits 226 
(97.5th percentile) varied widely from one assay to another, in both men and women (Figure 227 
1). Although the pre-analytic conditions were the same for the six kits, and although four of 228 
the six kits were calibrated against the international reference standard 02/254, concordance 229 
between the assays, as assessed with Bland-Altman plots and the Kappa coefficient, remained 230 
quite variable, not only for raw IGF-I values but also for IGF-I SDS. This latter result was 231 
somewhat surprising, as we expected that, by using the same healthy population, we would 232 
obtain similar SDS.  233 
In table 2, which shows the reference ranges for each assay, we have deliberately 234 
omitted the mean and SD calculated for each age category from the raw values, in order to 235 
avoid erroneous calculations of SDS. Indeed, the Box-Cox power transformation, which is 236 
necessary because of the non Gaussian distribution in each age category, uses parameters (L 237 
for skewness, M for median and S for the coefficient of variation) that are specific to each 238 
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assay and also to each age group and gender. We thus propose an online calculator available 239 
either following this link (http://ticemed_sa.upmc.fr/sd_score/) or by using Apps (IGF-I 240 
SD_score) downloadable for Android from Google Play and for iOS from Apple Store (free 241 
of charge) which allows to determine SDS as a function of the assay method, the measured 242 
IGF-I value, gender, and age. L, M and S parameters are also provided in Supplemental Table 243 
1. 244 
Reliable reference intervals are crucial for interpreting IGF-I values in adults with 245 
acromegaly (for diagnosis and assessment of disease control during treatment), and also for 246 
diagnosing GH deficiency and monitoring GH therapy (4,5,19,20). Reference intervals 247 
obtained with the IGF-I Nichols Advantage assay in a very large population of healthy 248 
subjects (21) were once widely used for research and clinical practice. However, market 249 
withdrawal of this assay, together with the availability of numerous automated methods with 250 
considerable heterogeneity, led to calls for improved comparability and reliable normative 251 
data. One important first step was the creation of the recombinant international IGF-I standard 252 
preparation 02/254 (22). A consensus conference held in 2011 proposed that all assays be 253 
calibrated against this standard, and advocated precise pre-analytical and analytical conditions 254 
(1). Another recommendation was to establish normative data based on a random selection of 255 
individuals from the background population, with representation of all age groups (1). The 256 
first normative data for the iSYS IGF-I assay, based on these recommendations and on a very 257 
large healthy population, were published by Bidlingmaier et al (23). We now propose 258 
reference intervals for six IGF-I assays also based on a large population of healthy subjects. It 259 
should be noted that we used very stringent inclusion criteria. Indeed, despite the large sample 260 
size (almost one thousand healthy subjects, with about 100 subjects per age group), all the 261 
subjects had a clinical examination, including assessment of gonadal status, and also a careful 262 
medical history taking that included ongoing medications. Furthermore, all the subjects had 263 
  -/22- 12 
an extensive standard biological work-up in order to exclude those with disorders capable of 264 
influencing IGF-I levels or their measurement. These very strict inclusion and exclusion 265 
criteria allow to define a population as “healthy” as possible; however this implies that these 266 
normative data will not be strictly applicable to patients with BMI > 28 kg/m2 or to patients 267 
with oral treatment with estrogens.    268 
As expected, IGF-I concentrations fell gradually with age in both sexes, irrespective of the 269 
assay. Contrary to previous reports (21,23), we found a gender difference, with higher IGF-I 270 
levels in women than in men, whatever the assay, until the 5th decade. After 50 years of age, 271 
however, IGF-I levels were higher in men than in women, as reported elsewhere (21,23). We 272 
therefore propose separate normative data for men and women. One possible explanation for 273 
the discrepancy between this work and previous reports is that we excluded all subjects 274 
receiving steroid hormones such as estrogens. Indeed, oral estrogen is known to lower IGF-1 275 
levels (6-8). In premenopausal women, for example, contraceptive pills containing ethinyl 276 
estradiol reduce IGF-I levels by up to an average of 30% (24-27). Another explanation might 277 
be the size of our population. Indeed, in their study involving a larger number of subjects 278 
(15,000), Bidlingmaier et al. did not find differences in terms of gender differences (23). 279 
Inter-assay differences in IGF-I reference intervals are a well-known issue that has 280 
previously been underlined by one of us (28,29) and by many other researchers 281 
(2,11,23,30,31). In this study, as expected, the largest inter-centile intervals (and highest 282 
values) were obtained with the two assays calibrated with the old standard IRP 87/518 283 
(IMMULITE and IGFI RIACT).  Moreover, the three automated methods (iSYS, Liaison XL 284 
and IMMULITE), which should theoretically be the most reproducible, did not yield narrower 285 
reference intervals. For example, the iSYS automated method and the Mediagnost RIA 286 
manual method gave very similar intervals for both men and women in all age groups.  Thus, 287 
the main source of variation does not appear to be analytical reproducibility. Using the same 288 
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iSYS method and a similar transformation for normalizing data and constructing specific 289 
centile curves in the LMS method, our 2.5th and 97.5th percentiles were generally slightly 290 
higher and our intervals generally narrower than those reported by Bidlingmaier et al. (23). 291 
Although inter-laboratory variability may play a role in these discrepancies, they are likely 292 
due mainly to differences in the population samples (our population was smaller, and the 293 
inclusion criteria were different). Another issue raised by our study is the poor concordance 294 
between our reference intervals and those proposed by the assay manufacturers. Once again 295 
this might be related to the use of different background populations: indeed, those used by 296 
manufacturers may not fulfill all the criteria recommended by the consensus group in 2011, 297 
particularly with respect to their size, the definition of healthy subjects, and the use of 298 
hormonal contraceptives (Supplemental Material). 299 
Likewise, one obvious explanation for the discordance between assays is the use of different 300 
populations to establish reference intervals. This is why we used the same reference 301 
population for all the kits. However, although the six assays showed comparable analytical 302 
performance in terms of their reproducibility and detection limits (Table 1), and despite the 303 
fact that they use the same non-competitive “sandwich” format and similar methods to avoid 304 
IGFBP interference (IGF-II addition), the reference values obtained in our well-controlled 305 
adult population differed strikingly from one assay to another. Two of the six assays 306 
(IMMULITE and IGF-I RIACT) are still calibrated against the old IRR 87/518 standard, 307 
whereas the other four are calibrated against the new IRR 02/254 standard, as currently 308 
recommended (1). As expected, the former two assays gave the highest upper reference range 309 
for both sexes until the age of 50 (Table 2, Figure 1). However, the reference ranges of two 310 
differently calibrated kits may be either similar (e.g. LIAISON XL and IGFI RIACT in men), 311 
or significantly different (e.g. iSYS lower than IMMULITE) (Table 2). Likewise, reference 312 
ranges determined with kits calibrated against the same reference preparation may also be 313 
  -/22- 14 
significantly different, even for kits from the same manufacturer (e.g. the RIA and ELISA kits 314 
from Mediagnost). It therefore seems likely that the observed differences are related to other 315 
analytical factors, such as the efficiency of IGFBP interference removal and the specificity 316 
and/or affinity of the antibody used. For example, since the 2.5th percentile is at least similar 317 
between the assays, the broadening of the interval for the IMMULITE assay is probably not 318 
related to the calibrator, but to relatively higher measurement results at the upper end:an 319 
explanation could be that IMMULITE assay preferentially recognizes the high free IGF-I at 320 
high concentrations, while the other 2 assays more efficiently remove the impact of BPs. 321 
This could have important implications in patients with disorders affecting their IGFBP 322 
profile, such as acromegaly and chronic kidney disease. If confirmed in further studies, this 323 
implies that a given individual must be monitored with the same IGF-I assay.  324 
Another limitation of our study is that it lies on a single measurement of IGF-I while it is well 325 
known that there is some within-subject variability when an individual is sampled on different 326 
days (32,33). 327 
What refinements may be expected in the measurement of this very demanding 328 
analyte? The LC-MSMS method may prove to be a valid alternative and is now being used to 329 
assess inter-laboratory agreement on IGF-I concentrations (34) or for validation of IGF-I 330 
measures (35). Reference intervals for IGF-I provided with this LC-MS (36) seem very 331 
comparable with those obtained with immunoassays.  When compared with our data, lower 332 
limit of normal range is similar and upper limit corresponds more or less with those observed 333 
with Liaison XL or IGF1 RIACT immunoaasays. However, LC-MSMS is a time-consuming 334 
and complex method that requires expensive machines and high technical expertise, because 335 
many variables need to be controlled for providing accurate quantitative results 336 
(e.g. extraction strategies, approaches to detect and quantify IGF-I, calibration 337 
protocols…)(37).  Furthermore, a recent preliminary study of an LC-MS method suggested 338 
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that it might miss some IGF-I protein variants (pathogenic or physiological), which are 339 
present in 0.6% of the population (38). Thus, despite their limitations, immunoassays will 340 
continue to be widely used, at least in the near future (39). 341 
In conclusion, we have established reference intervals for six commercial IGF-I 342 
assays, in a study conforming to recent international recommendations. Despite being 343 
obtained in the same large population of French healthy subjects, the reference intervals 344 
differed somewhat from one assay to another, and agreement between assays was moderate to 345 
good. Finally, concordances between the manufacturers' reference intervals and those 346 
obtained in our cohort were generally poor. These findings confirm the need to establish 347 
reference intervals for each commercial IGF-I assay in a large background population. Inter-348 
assay concordance with respect to the classification of patients with acromegaly or GH 349 
deficiency remains to be determined, and the IGF-I standard deviation scores obtained with 350 
the six assays in these subjects need to be compared. 351 
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Legends of Figures 362 
Figure 1. 363 
Reference intervals (Upper panel, males; lower panel, females) according to the age intervals 364 
of the 6 immunoassays tested.  Lower limits (2.5th percentile) and upper limits (97.5th 365 
percentile) of the normal range are drawn as full lines and means as dotted lines. 366 
 367 
Figure 2. 368 
Comparisons between iSYS and Mediagnost RIA expressed as scatter plots (A) or Bland-369 
Altman plots (B) for raw data, or scatter plots (C) and Bland-Altman plots (D) for SDS 370 
showing a good overall agreement between both immunoassays, with no significant bias.  371 
Comparisons between Liaison XL and Mediagnost RIA expressed as scatter plots (E) or 372 
Bland-Altman plots (F) for raw data, or scatter plots (G) and Bland-Altman plots (H) for SDS 373 
showing a bad overall agreement between these two immunoassays. 374 
 375 
 376 
 377 
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Table 1 :Characteristics of the tested IGF-I assays as provided by the manufacturers. These 6 assays are sandwich assays that use a couple of monoclonal antibodies directed against epitopes 
whose exact nature is not disclosed by the manufacturers. In all cases, IGFBPs are said to be removed by displacement of endogenous IGF-I by an excess of IGF-II (or analog) as initially 
proposed by Blum and Breier (13). The limit of quantification (LOQ) is the lowest amount of IGF-I that can be accurately quantified with an allowable error <20%. The limit of detection (LOD) 
is the IGF-I concentration corresponding to the 95th percentile value from a number of determinations of IGF-I concentration in free serum samples. 
 
Name of the 
assay 
Manu- 
facturer 
Auto
mated 
Tracer International 
standard 
against 
which the 
assay is 
calibrated 
Intra-assay CV Inter-assay CV  LOQ or  
LOD in ng/mL 
Highest 
measurab
le value 
without 
dilution 
(ng/mL) 
Reference adult population 
recruited  
by the manufacturer 
iSYS  IDS Yes Acridinium 
ester 
WHO/NIBSC 
02/254 
2.9% at 22 ng/mL 
1.9% at 163 ng/mL 
4.2% at 304 ng/mL 
5.4% at 22 ng/mL 
3.9% at 163 ng/mL 
7.2% at 304 ng/mL 
8.8 (LOQ) 1200  6500 adults. Reference values 
provided according to the method 
of Cole and Green) (12) 
LIAISON XL DiaSorin Yes isoluminol WHO/NIBSC 
02/254 
5.1% at 70 ng/mL 
3.5% at 183 ng/mL 
3% at 589 ng/mL 
9.6% at 80 ng/mL 
7.1% at 187 ng/mL 
5.6% at 317 ng/mL 
3 (LOD) 
10 (LOQ) 
1500 1606 adults. Reference values 
provided by age according to the 
method of Royston and Wright 
(14) 
IMMULITE 
2000 
Siemens Yes Alkaline 
phosphatase 
WHO/NIBSC 
1st IRR 
87/518 
3.9% at 77 ng/mL 
6.5% at 169 ng/mL 
2.9% at 380 ng/mL 
3.0% at 689 ng/mL 
2.3% at 1053 ng/mL 
2.4% at 1358 ng/mL 
7.7% at 77 ng/mL 
5.4% at 169 ng/mL 
7.4% at 380 ng/mL 
8.1% at 689 ng/mL 
3.7% at 1053 ng/mL 
4.7% at 1358 ng/mL 
20 (LOQ) 1600 1499 pediatric and adult samples 
from an apparently healthy 
population (no indication is given 
concerning the respective numbers 
of adult and children) 
IGFI- RIACT Cisbio No 125I WHO/NIBSC 
1st IRR 
87/518 
3.8% at 49 ng/mL 
3.4% at 162 ng/mL 
3.2% at 496 ng/mL 
3.8 % at 39 ng/mL 
8.2 % at 352 ng/mL 
5.9 % at 509 ng/mL 
1 (LOD) 900 693 adults 29-70 years 
 
Mediagnost 
ELISA 
MEDIA- 
GNOST 
No Peroxydase 
enzyme 
conjugate 
WHO/NIBSC 
02/254 
5.7% at 138 ng/mL 
5.1% at 141 ng/mL 
6.6% at 145 ng/mL 
6.1 % at 142 ng/mL 
6.8 % at 174 ng/mL 
2.2 % at 494 ng/mL 
1.9 (LOD) 1050 Based on the data reported by 
Blum and Breier (13) 
Mediagnost 
RIA 
MEDIA- 
GNOST 
No 125I WHO/NIBSC 
02/254 
4.6% at 56 ng/mL 
3.4% at 140 ng/mL 
2.5% at 180 ng/mL 
4.9 % at 55 ng/mL 
6.2 % at 140 ng/mL 
4.5 % at 186 ng/mL 
2.6 (LOD) 780 Based on the data reported by 
Blum and Breier (13) 
The reference values for the 
different age ranges are the same 
as those used for the Mediagnost 
ELISA kit 
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Table 2.Normative reference intervals (95% confidence interval : CI) of IGF-I measured by 6 assay methods according to age range and sex in a cohort of 899 
healthy subjects  
 
Age range N iSYS  
IGF-I (ng/mL)  
95%CI 
LIAISON XL  
IGF-I (ng/mL)  
95%CI  
IMMULITE 2000  
IGF-I (ng/mL) 
95%CI 
IGFI-RIACT  
IGF-I (ng/mL) 
95%CI 
Mediagnost ELISA 
 IGF-I (ng/mL) 
95%CI 
Mediagnost RIA 
IGF-I (ng/mL)  
95%CI 
Males        
18-20 years 56 168-391 186-453 195-537 197-486 177-430 168-374 
21-23 years 61 147-346 168-411 171-477 173-430 159-388 150-337 
24-26 years 53 132-313 153-377 152-430 155-389 144-355 135-308 
27-29 years 49 122-292 142-351 138-396 143-363 133-331 126-289 
30-39 years 56 108-265 124-310 118-348 127-329 115-295 112-265 
40-49 years 51 91-233 106-271 98-301 107-286 98-261 97-237 
50-59 years 54 81-214 97-252 85-273 94-262 88-245 86-218 
60-69 years 49 75-208 92-245 77-260 87-250 80-237 82-214 
70-89 years 34 64-192 80-220 66-242 75-231 71-233 72-200 
        
Females        
18-20 years 41 155-421 191-483 180-586 169-517 169-487 161-412 
21-23 years 54 144-383 176-448 166-541 159-476 156-446 149-379 
24-26 years 45 134-353 163-418 153-501 150-440 144-412 139-353 
27-29 years 48 126-330 152-391 142-467 142-410 134-385 131-332 
30-39 years 47 113-294 131-345 121-403 126-356 118-341 118-298 
40-49 years 50 97-253 109-296 98-331 107-297 100-296 103-258 
50-59 years 54 80-209 93-253 80-271 90-247 82-248 97-220 
60-69 years 47 64-170 84-222 68-227 76-209 68-208 75-190 
70-89 years 50 56-154 81-204 60-188 67-189 60-187 68-175 
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Table 3. Agreement of each IGF-1 assay method against each of the other, expressed as 
weighted kappa and percentages of observed agreement. 
 
 
 
LIAISON 
XL 
iSYS 
IMMULITE 
2000 
Mediagnost 
ELISA 
Mediagnost 
RIA 
IGFI- 
RIACT 
LIAISON XL - 
0.49 
94.86% 
0.50 
94.83% 
0.47 
94.95% 
0.38 
94.05% 
0.48 
95.22% 
iSYS 
0.49 
94.86% 
- 
0.64 
96.08% 
0.61 
96.11% 
0.70 
97.00% 
0.64 
96.46% 
IMMULITE 
2000 
0.50 
94.83% 
0.64 
96.08% 
- 
0.61 
95.95% 
0.58 
95.73% 
0.64 
96.32% 
Mediagnost 
ELISA 
0.47 
94.95% 
0.61 
96.11% 
0.61 
95.95% 
- 
0.59 
96.00% 
0.53 
95.66% 
Mediagnost 
RIA 
0.38 
94.05% 
0.70 
97.00% 
0.58 
95.73% 
0.59 
96.00% 
- 
0.48 
95.22% 
IGFI- 
RIACT 
0.48 
95.22% 
0.64 
96.46% 
0.64 
96.32% 
0.53 
95.66% 
0.48 
95.22% 
- 
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Table 4. Concordance between VARIETE cohort reference intervals and reference 
intervals provided by each manufacturer, expressed as Kappa and percentages of 
observed agreement 
 
 
LIAISON 
XL 
iSYS 
IMMULITE 
2000 
Mediagnost 
ELISA 
Mediagnost 
RIA 
IGFI -
RIACT 
Weighted 
Kappa  
0.19 0.35 0.38 0.18 0.17 0.22 
% of 
agreement 
83.28 93.36 86.97 93.55 94.77 88.21 
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